Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK/mTOR mediated autophagy pathway

Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats

(2021) Krit Jaikumkao et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors

(2021) Ralph A. DeFronzo et al.   Nature Reviews Nephrology

The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway

(2021) Ziyu Meng et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Interplay of adenosine monophosphate‐activated protein kinase/sirtuin‐1 activation and sodium influx inhibition mediates the renal benefits of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: A novel conceptual framework

(2020) Milton Packer   DIABETES OBESITY & METABOLISM

Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors

(2020) Milton Packer   EUROPEAN JOURNAL OF HEART FAILURE

Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance

(2020) Milton Packer   CIRCULATION

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes

(2020) Anton I. Korbut et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition

(2020) Issei Tomita et al.   Cell Metabolism

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Import of extracellular ATP in yeast and man modulates AMPK and TORC1 signalling

(2019) Gabriella M. Forte et al.   JOURNAL OF CELL SCIENCE

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

(2019) Ofri Mosenzon et al.   Lancet Diabetes & Endocrinology

Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

(2019) Alana Aragón-Herrera et al.   BIOCHEMICAL PHARMACOLOGY

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells

(2018) Chenke Xu et al.   BIOCHEMICAL PHARMACOLOGY

Autophagy in health and disease: A comprehensive review

(2018) Sarbari Saha et al.   BIOMEDICINE & PHARMACOTHERAPY

Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli

(2018) Xiaodan Wang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Advanced glycation end-products suppress autophagic flux in podocytes by activating mammalian target of rapamycin and inhibiting nuclear translocation of transcription factor EB

(2018) Xingchen Zhao et al.   JOURNAL OF PATHOLOGY

Cinacalcet-mediated activation of the CaMKKβ-LKB1-AMPK pathway attenuates diabetic nephropathy in db/db mice by modulation of apoptosis and autophagy

(2018) Ji Hee Lim et al.   Cell Death & Disease

Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy

(2017) Hengjiang Guo et al.   Scientific Reports

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

5'-Monophosphate-activated protein kinase (AMPK) improves autophagic activity in diabetes and diabetic complications

(2016) Fan Yao et al.   Acta Pharmaceutica Sinica B

Emerging role of podocyte autophagy in the progression of diabetic nephropathy

(2015) Mako Yasuda-Yamahara et al.   Autophagy

Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis

(2015) A. Ojima et al.   HORMONE AND METABOLIC RESEARCH

Autophagy in diabetic nephropathy

(2014) Yan Ding et al.   JOURNAL OF ENDOCRINOLOGY

Emerging role of autophagy in kidney function, diseases and aging

(2012) Tobias B. Huber et al.   Autophagy

AMPK: a nutrient and energy sensor that maintains energy homeostasis

(2012) D. Grahame Hardie et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A comprehensive glossary of autophagy-related molecules and processes (2ndedition)

(2011) Daniel J Klionsky et al.   Autophagy

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice

(2011) Markus Gödel et al.   JOURNAL OF CLINICAL INVESTIGATION

mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice

(2011) Ken Inoki et al.   JOURNAL OF CLINICAL INVESTIGATION

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

(2011) Joungmok Kim et al.   NATURE CELL BIOLOGY